Literature DB >> 20593284

Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study.

Susanna Jakobson Mo1, Jan Linder, Lars Forsgren, Anne Larsson, Lennart Johansson, Katrine Riklund.   

Abstract

PURPOSE: The aim of this study was to assess the diagnostic contribution of pre- and postsynaptic dopamine SPECT in drug-naïve patients with early idiopathic parkinsonism and to investigate possible differences between idiopathic Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) and possible differences in motor subtypes of parkinsonism.
METHODS: A group of 128 newly diagnosed idiopathic parkinsonian patients and 48 healthy controls was studied. Presynaptic baseline SPECT with (123)I-FP-CIT was performed in all patients and in 120 patients also a baseline postsynaptic SPECT with (123)I-IBZM. Clinical diagnoses were reassessed after 12 months.
RESULTS: Presynaptic uptake in the putamen and caudate was significantly reduced in patients compared to controls. Presynaptic uptake ratios were not different between PD patients and patients with APS, and postsynaptic uptake in APS was not significantly reduced compared to PD or controls. In half of the APS patients both pre- and postsynaptic uptake ratios were reduced on the same side in the striatum. Impaired motor performance was associated with decreased presynaptic uptake in the putamen in PD. The postural instability and gait difficulty (PIGD) subtype of PD had lower presynaptic uptake ratios than patients with tremor-dominated (TD) symptoms.
CONCLUSION: Not only presynaptic putamen uptake ratios, but also caudate ratios were reduced in a majority of the patients in our study. At baseline scan, i.e. in an early stage of the disease, the accuracy of excluding APS in the whole study population was 85% using a combination of pre- and postsynaptic SPECT. Already at baseline, lower presynaptic SPECT ratios were seen in PD with PIGD at onset compared to those with TD subtype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20593284     DOI: 10.1007/s00259-010-1520-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

1.  Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Authors:  H T Benamer; J Patterson; D J Wyper; D M Hadley; G J Macphee; D G Grosset
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

Review 2.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

3.  Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.

Authors:  E van Royen; N F Verhoeff; J D Speelman; E C Wolters; M A Kuiper; A G Janssen
Journal:  Arch Neurol       Date:  1993-05

Review 4.  Role of DAT-SPECT in the diagnostic work up of parkinsonism.

Authors:  Christoph Scherfler; Johannes Schwarz; Angelo Antonini; Donald Grosset; Francesc Valldeoriola; Kenneth Marek; Wolfgang Oertel; Eduardo Tolosa; Andrew J Lees; Werner Poewe
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

Review 5.  Role of dopamine transporter imaging in routine clinical practice.

Authors:  Vicky Marshall; Donald Grosset
Journal:  Mov Disord       Date:  2003-12       Impact factor: 10.338

6.  Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.

Authors:  Ana M Catafau; Santiago Bullich; Mónica Danús; María M Penengo; Albert Cot; Sergio Abanades; Magí Farré; Javier Pavía; Domènec Ros
Journal:  Synapse       Date:  2008-01       Impact factor: 2.562

7.  Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.

Authors:  J Schwarz; A Antonini; K Tatsch; C M Kirsch; W H Oertel; K L Leenders
Journal:  Nucl Med Commun       Date:  1994-10       Impact factor: 1.690

8.  Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.

Authors:  Valentina Berti; Alberto Pupi; Silvia Ramat; Eleonora Vanzi; Maria Teresa De Cristofaro; Giannantonio Pellicanò; Francesco Mungai; Paolo Marini; Sandro Sorbi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-23       Impact factor: 9.236

9.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

10.  Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

Authors:  D Aarsland; K Brønnick; J P Larsen; O B Tysnes; G Alves
Journal:  Neurology       Date:  2008-11-19       Impact factor: 9.910

View more
  11 in total

Review 1.  [Helpful instrumental examinations in idiopathic Parkinson's disease].

Authors:  U Walter; H Zach; I Liepelt-Scarfone; W Maetzler
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

2.  The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.

Authors:  Charalampos Georgiopoulos; Anette Davidsson; Maria Engström; Elna-Marie Larsson; Helene Zachrisson; Nil Dizdar
Journal:  J Neurol       Date:  2015-06-30       Impact factor: 4.849

3.  Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease.

Authors:  Sebastian J Brandl; Stefan Braune
Journal:  Clin Auton Res       Date:  2018-06-05       Impact factor: 4.435

4.  Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Katrine Riklund
Journal:  Mov Disord Clin Pract       Date:  2014-09-30

5.  Diffusion tensor imaging and correlations to Parkinson rating scales.

Authors:  Niklas Lenfeldt; William Hansson; Anne Larsson; Lars Nyberg; Richard Birgander; Lars Forsgren
Journal:  J Neurol       Date:  2013-08-23       Impact factor: 4.849

6.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

7.  LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity.

Authors:  Hui-Fang Liu; Song Lu; Philip Wing-Lok Ho; Ho-Man Tse; Shirley Yin-Yu Pang; Michelle Hiu-Wai Kung; Jessica Wing-Man Ho; David B Ramsden; Zhong-Jun Zhou; Shu-Leong Ho
Journal:  Ann Clin Transl Neurol       Date:  2014-03-04       Impact factor: 4.511

8.  Pre- and postsynaptic dopamine SPECT in idiopathic Parkinsonian diseases: a follow-up study.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Henrik Holmberg; Anne Larsson; Katrine Riklund
Journal:  Biomed Res Int       Date:  2013-09-19       Impact factor: 3.411

9.  Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study.

Authors:  David Bäckström; Gabriel Granåsen; Magdalena Eriksson Domellöf; Jan Linder; Susanna Jakobson Mo; Katrine Riklund; Henrik Zetterberg; Kaj Blennow; Lars Forsgren
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

10.  NfL as a biomarker for neurodegeneration and survival in Parkinson disease.

Authors:  David Bäckström; Jan Linder; Susanna Jakobson Mo; Katrine Riklund; Henrik Zetterberg; Kaj Blennow; Lars Forsgren; Niklas Lenfeldt
Journal:  Neurology       Date:  2020-07-17       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.